Scholarlink

Introduction <p>Robust evidence endorsed by the International Agency for Research on Cancer demonstrates that excess body fat represents a risk for the development of at least 13 types of cancer.</p> Objective <p>We investigated the serum of individuals with obesity who had no history of cancer (either personal or familial) to identify biomarkers.</p> Methods <p>45 individuals were included in this study; they did not show significant differences regarding age, sex, or physical activity. A quality-of-life questionnaire was administered to all participants, revealing that the obese group self-reported difficulties in functional capacity and a greater association with comorbidities, notably hypertension. FTIR, metabolomic, and lipidomic analyses were performed to identify spectral peaks, metabolic, and lipids differentiating between the NO (non-obese) and OB (obese) groups.</p> Results <p>The identified peaks are predominantly associated with profiles of lipids, carbohydrates, and nitrogenous compounds. A total of six metabolites and lipids were identified at different levels in the serum of the OB group that have a direct relationship with the development or metabolism of cancer cells (three metabolites and three lipids). Among these, some suggest a reduced likelihood of cancer development, while others indicate an increased potential for cancer development. In this context, we can highlight two substances: the metabolite 4-Hydroxyphenylglyoxylate, which is reduced in the serum of individuals with obesity, and the lipid Glycidyl palmitate, which is elevated in individuals with obesity.</p> Conclusion <p>4-Hydroxyphenylglyoxylate and Glycidyl palmitate can be used as biomarkers for cancer and obesity correlation. New experiments manipulating these substances may contribute to a better understanding of their interactions with cancer cells.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Exploring the potential relationship between serum biomarkers in obese individuals and cancer using FTIR, metabolomics, and lipidomics

  • 期刊论文

  • 发表日期：

    2025年11月3日

查看全文
  • Maria Eduarda Marques,
  • Natália Ferreira Silva,
  • Fernanda Naves Araújo do Prado Mascarenhas,
  • Tatiana Carla Tomiosso,
  • Robson José de Oliveira Júnior,
  • Ricardo Rodrigues,
  • Hebreia Oliveira Almeida-Souza,
  • Mário Machado Martins,
  • Luciana Machado Bastos,
  • Arlene Bispo dos Santos Nossol,
  • Tiara da Costa Silva,
  • Camila Moreira de Andrade,
  • Marco Fidel Guevara-Vega,
  • Robinson Sabino-Silva,
  • Carlos Ueira-Vieira,
  • Renata Graciele Zanon

摘要

Introduction

Robust evidence endorsed by the International Agency for Research on Cancer demonstrates that excess body fat represents a risk for the development of at least 13 types of cancer.

Objective

We investigated the serum of individuals with obesity who had no history of cancer (either personal or familial) to identify biomarkers.

Methods

45 individuals were included in this study; they did not show significant differences regarding age, sex, or physical activity. A quality-of-life questionnaire was administered to all participants, revealing that the obese group self-reported difficulties in functional capacity and a greater association with comorbidities, notably hypertension. FTIR, metabolomic, and lipidomic analyses were performed to identify spectral peaks, metabolic, and lipids differentiating between the NO (non-obese) and OB (obese) groups.

Results

The identified peaks are predominantly associated with profiles of lipids, carbohydrates, and nitrogenous compounds. A total of six metabolites and lipids were identified at different levels in the serum of the OB group that have a direct relationship with the development or metabolism of cancer cells (three metabolites and three lipids). Among these, some suggest a reduced likelihood of cancer development, while others indicate an increased potential for cancer development. In this context, we can highlight two substances: the metabolite 4-Hydroxyphenylglyoxylate, which is reduced in the serum of individuals with obesity, and the lipid Glycidyl palmitate, which is elevated in individuals with obesity.

Conclusion

4-Hydroxyphenylglyoxylate and Glycidyl palmitate can be used as biomarkers for cancer and obesity correlation. New experiments manipulating these substances may contribute to a better understanding of their interactions with cancer cells.